- Home
- GBR vs ENVB Comparison
GBR vs ENVB Comparison
Compare GBR & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GBR | ENVB |
|---|---|---|
| Founded | 1978 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7M | 3.0M |
| IPO Year | 1995 | 2000 |
Fundamental Metrics
Financial Performance| Metric | GBR | ENVB |
|---|---|---|
| Price | $0.89 | $1.96 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 557.1K | 252.4K |
| Earning Date | 03-20-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $146,000.00 | ★ $39,914,675.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.67 | $0.56 |
| 52 Week High | $1.78 | $13.25 |
Technical Indicators
Market Signals| Indicator | GBR | ENVB |
|---|---|---|
| Relative Strength Index (RSI) | 49.68 | 37.08 |
| Support Level | $0.81 | $1.96 |
| Resistance Level | $0.90 | $4.29 |
| Average True Range (ATR) | 0.16 | 0.11 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 19.64 | 23.14 |
Price Performance
Historical ComparisonAbout GBR New Concept Energy Inc
New Concept Energy Inc is a United States-based company engaged in Real Estate Operations. It intends to continue to operate and or sell its West Virginia property. It provides advisory and management services for an independent West Virginia oil and gas company. The Company seeks to establish or acquire new business operations. It operates in one segment, which is real estate rental.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.